Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2003-132 – Mayo Clinic has patent rights claiming methods of detecting the autoantibody associated with NMO.
2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2013-206 – This invention has benefit over other methods since it directly quantitates the mAb without the need for interaction with the antigen. By monitoring tryptic peptides from the unique variable regions of the therapeutic mAb and comparing them to the constant regions of a non-human antibody added as an internal standard, the mAb can be measured. This method is superior to other methods using... Read More
2011-176 – Calcitonin gene related peptide (CGRP) and Substance P (SP) were elevated in the nasal secretions of patients with postnasal drip who also have chronic cough compared to levels from nasal secretions from patients without cough. A point-of-care test which can assay the level of CGRP and SP may be helpful in predicting whether or not chronic cough is due to postnasal drip.
2009-379 – Technology Description Patients with extensive, longstanding inflammatory bowel diseases (ulcerative colitis or Crohn’s disease), which are diseases of chronic colonic inflammation, are at risk for colorectal cancer (CRC). Surveillance of this at-risk population remains challenging. Mayo Clinic researchers have identified biomarkers for colorectal cancer in inflammatory bowel disease... Read More
2007-012 – Technology Description The past 20 years have witnessed an unprecedented increase in eosinophil-associated diseases such as allergy, asthma, and inflammatory gastrointestinal syndromes. Despite this rise in the need for an eosinophil-specific assay few reagents are available. Mayo Clinic researchers have developed a unique monoclonal antibody reactive to the eosinophil specific protein... Read More
2006-018 – Technology Description B7-H4 is a cell surface protein whose expression on tumor cells and tumor-associated vasculature is greatly increased in renal cancers. B7-H4 expression levels on renal tumors have been shown to be a predictor of tumor aggressiveness and to increase mortality rates. B7-H4 is highly expressed on tumors and tumor-associated vasculature but not on normal tissues and... Read More